Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Clinically Relevant Updates in Dermatopathology: Where are the Gaps? An Update on Melanocytic Lesions
Description
The talk covers recent advancements and gaps in dermatopathology, particularly focusing on melanocytic lesions. Dr. Junkins provides insights on the use of immunohistochemistry, molecular techniques, and artificial intelligence in improving diagnostic accuracy. The presentation emphasizes the importance of PRAME as a promising tool in differentiating between melanomas and other conditions, especially in challenging diagnostic scenarios. It highlights studies showcasing PRAME's utility in various cases and discusses the specificity and sensitivity issues that still need addressing. The role of AI in analyzing melanocytic lesions is explored, with potential benefits and concerns regarding the accuracy of training data used for machine learning highlighted. Furthermore, the decline in melanoma mortality despite an increase in diagnoses prompts a reconsideration of diagnostic criteria and the possibility of overdiagnosis. The need for integrating multiple approaches, including clinical findings and newer genetic profiling techniques, is underscored as essential for refining treatment strategies. The discussion concludes with a call for dermatopathologists to continually reassess diagnostic methodologies, particularly in light of emerging phenomena such as fusion neoplasms, while maintaining accuracy in educating AI systems to ensure meaningful patient outcomes.
View moreConclusions
- PRAME serves as a relatively sensitive and specific marker for malignant melanocytic phenotype and shows promise for diagnosing Spitz neoplasms.
- Immunohistochemistry, involving PRAME, could assist in diagnosing and managing challenging melanocytic lesions.
- Artificial Intelligence is beginning to play a role in dermatopathology, though there are gaps in practical application.
- Reductions in diagnostic errors can be achieved through the use of comprehensive tools, including second opinions and molecular diagnostics.
- Overdiagnosis of melanoma is a significant issue, leading to unnecessary treatments and anxiety among patients.
- Training in dermatopathology impacts diagnostic accuracy, with specialists more likely to assign higher-grade diagnoses.
- Gene expression profiling (GEP) is a valuable ancillary diagnostic tool for ambiguous melanocytic tumors, aiding in decision-making.
- Molecular testing is becoming increasingly integrated into dermatopathology, enhancing diagnostic accuracy for melanocytic lesions.
- Lezcano C, Jungbluth AA, Busam KJ. Immunohistochemistry for PRAME in Dermatopathology. The American journal of dermatopathology. 2023;45(11):733-747. doi:10.1097/DAD.0000000000002440
- Hornick JL, Plaza JA, Mentzel T, Gru AA, Brenn T. PRAME Expression Is a Useful Tool in the Diagnosis of Primary and Metastatic Dedifferentiated and Undifferentiated Melanoma. Am J Surg Pathol. 2023 Dec 1;47(12):1390-1397. doi: 10.1097/PAS.0000000000002125. Epub 2023 Sep 19. PMID: 37727938.
- Innocenti L, Scarpitta R, Corraro S, Ortenzi V, Bonadio AG, Loggini B, De leso K, Naccarato AG, Fanelli GN, Scatena C. Shedding light on PRAME expression in dysplastic nevi: a cohort study. Virchows Arch. 2023 Dec 19. doi: 10.1007/s00428-023-03720-5. Epub ahead of print. PMID: 38112793.
- Casillas AC, Muhlbauer A, Barragan VA, Jefferson I, Speiser JJ. A Comparison of Preferentially Expressed Antigen in Melanoma Immunohistochemistry and Diagnostic Gene Expression-Profiling Assay in Challenging Melanocytic Proliferations. Am J Dermatopathol. 2024 Mar 1;46(3):137-146. doi: 10.1097/DAD.0000000000002501. Epub 2023 Dec 13. PMID: 38354382.
- Koch EAT, Erdmann M, Berking C, Kiesewetter F, Kramer R, Schliep S, Heppt MV. Standardized Computer-Assisted Analysis of PRAME Immunoreactivity in Dysplastic Nevi and Superficial Spreading Melanomas. Int J Mol Sci. 2023 Mar 28;24(7):6388. doi: 10.3390/ijms24076388. PMID: 37047361; PMCID: PMC10094429.
- Elder DE, Eguchi MM, Barnhill RL, Kerr KF, Knezevich SR, Piepkorn MW, Reisch LM, Elmore JG. Diagnostic error, uncertainty, and overdiagnosis in melanoma. Pathology. 2023 Mar;55(2):206-213. doi: 10.1016/j.pathol.2022.12.345. Epub 2022 Dec 29. PMID: 36642569; PMCID: PMC10373372.
- Marks E, Jarell A, Ludzik J, Farberg AS, Rabinovitz HS, Phelps RG, Cockerell CJ, Witkowski A. A Physician's Guide to the Use of Gene Expression Profile Ancillary Diagnostic Testing for Cutaneous Melanocytic Neoplasms. J Clin Aesthet Dermatol. 2023 Apr;16(4):12-20. PMID: 37077930; PMCID: PMC10110288.
- Huang C, Lau TW-S, Smoller BR. Diagnosing Cutaneous Melanocytic Tumors in the Molecular Era: Updates and Review of Literature. Dermatopathology. 2024; 11(1):26-51. doi: 10.3390/dermatopathology11010005.
- Hagstrom M, Dhillon S, Fumero-Velázquez M, Olivares S, Gerami P. A reappraisal of the epidemiology of Spitz neoplasms in the molecular era: A retrospective cohort study. J Am Acad Dermatol. 2023 Dec;89(6):1185-1191. doi: 10.1016/j.jaad.2023.08.005. Epub 2023 Aug 9. PMID: 37567480.